SecBot SecBot
8-K ·Filed Jun 30, 2026

PVLA

PALVELLA THERAPEUTICS, INC.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001104659-26-079087
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine board appointment with no immediate trading catalyst. Monitor for any future strategic moves given Mr. Pauls' rare disease and M&A background, but no actionable signal from this filing alone.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$152.82
T+0 close · Jun 30, 2026 · via day close
Latest settled
−2.13%
T+60 · $149.56
Vs SPY
−5.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $152.82entry
  2. T+1 · 5mo ago −9.53%α −9.39% · $138.26
  3. T+5 · 4mo ago −8.19%α −8.79% · $140.31
  4. T+20 · 4mo ago −7.23%α −6.20% · $141.77
  5. T+60 · 8w ago −2.13%α −5.70% · $149.56
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics appointed Matthew Pauls as a Class I director, expanding the board from seven to eight members. Mr. Pauls is the CEO of Savara, Inc. and brings rare disease and commercialization experience, including a prior board role at Soleno Therapeutics through its $2.9B acquisition. This is a routine board appointment with no material financial impact.

Key Facts

  • Board expanded from 7 to 8 members on June 29, 2026
  • Matthew Pauls appointed as Class I director, term expiring at 2027 Annual Meeting
  • Mr. Pauls is CEO of Savara, Inc. (NASDAQ: SVRA)
  • Granted option to purchase 6,000 shares vesting monthly over 36 months
  • No related party transactions or family relationships with existing directors/officers
  • Board determined Mr. Pauls is independent under Nasdaq rules

Financial Impact

Standard non-employee director compensation, option for 6,000 shares with 36-month vesting; annual retainer per policy. Immaterial relative to $2.1B market cap.

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-079087
Document: 0001104659-26-079087-index-headers.html0001104659-26-079087
Document: 0001104659-26-079087-index.html0001104659-26-079087
Document: 0001104659-26-079087.txt0001104659-26-079087

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 30, 2026